Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Arabinonucleosides
/ adverse effects
Child
Cyclophosphamide
/ adverse effects
Etoposide
/ adverse effects
Humans
Lymphoma, Non-Hodgkin
/ drug therapy
Nucleosides
/ therapeutic use
Plant Nectar
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
/ pathology
Recurrence
T-cell leukemia
chemotherapy
childhood ALL
nelarabine/cyclophosphamide/etoposide
relapse/refractory
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
02
07
2022
received:
26
02
2022
accepted:
06
07
2022
pubmed:
23
8
2022
medline:
1
10
2022
entrez:
22
8
2022
Statut:
ppublish
Résumé
Children with relapse of T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) have a dismal prognosis, largely due to difficulty attaining second remission. We hypothesized that adding etoposide and cyclophosphamide to the nucleoside analog nelarabine could improve response rates over single-agent nelarabine for relapsed T-ALL and T-LBL. This phase I dose-escalation trial's primary objective was to evaluate the dose and safety of nelarabine given in combination with etoposide at 100 mg/m
Substances chimiques
Arabinonucleosides
0
Nucleosides
0
Plant Nectar
0
nelarabine
60158CV180
Etoposide
6PLQ3CP4P3
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29901Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Pui C-H, Relling MV, Downing JR. Mechanisms of disease: acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535-1548.
Pui C-H. Childhood leukemias. N Engl J Med. 1995;332(24):1618-1630.
Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood. 1998;91(3):735-746.
Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the Children's Cancer Group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group report. Leukemia. 2010;24(2):285-297.
Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the Pediatric Oncology Group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children's Oncology Group. Leukemia. 2010;24(2):355-370.
Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265-284.
Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010;24(2):320-334.
Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95(2):416-421.
Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335-342.
Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med. 1996;334(19):1238-1248.
Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience. J Clin Oncol. 2003;21(19):3616-3622.
Reismüller B, Attarbaschi A, Peters C, et al. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria-a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Br J Haematol. 2008;144(4):559-570.
Eckert C, Parker C, Moorman AV, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021;151:175-189. doi:10.1016/j.ejca.2021.03.034 PMID: 34010787
Kisor DF, Plunkett W, Kurtzberg J, et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000;18(5):995-1003.
Rodriguez CO Jr, Mitchell BS, Ayres M, et al. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002;62(11):3100-3105.
Carson DA, Kaye J, Matsumoto S, et al. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci USA. 1979;76(5):2430-2433.
Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005;23(15):3396-3403.
Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005;23(15):3376-3382.
Cohen MH, Johnson JR, Justice R, Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist. 2008;13(6):709-714.
Zwaan CM, Kowalczyk J, Schmitt C, et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol. 2017;179:284-293.
Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study. J Clin Oncol. 2008;26(22):3756-3762.
Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol. 2009;147(3):371-378.
Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118(23):6043-6049.
Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708-720.
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria in non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(4):1244-1253.
Khan MA, Wakefield GS, Pugh DW. Vitamin-B12 deficiency and diabetic neuropathy. Lancet North Am Ed. 1969;294(7624):768-770.
Papayannidis C, Iacobucci I, Abbenante MC, et al. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. Am J Hematol. 2010;85(8):608-608.
Horton TM, Lu X, O'Brien MM, et al. AALL07P1: bortezomib with reinduction chemotherapy for first relapsed pediatric ALL. A Children's Oncology Group study. Pediatr Blood Cancer. 2014;61(S2):S137-138.
Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102(7):2379-2386.
Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24(12):1917-1923.
Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3):an open-label randomised trial. Lancet. 2010;376(9757):2009-2017.
Hongo T, Fujii Y. In vitro chemosensitivity of lymphoblasts at relapse in childhood leukemia using the MTT assay. Int J Hematol. 1991;54(3):219-230.
Behrendt H, Massar CG, van Leeuwen EF. Mitoxantrone is effective in treating childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia. Cancer. 1995;76(2):339-342.
DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109(12):5136-5142.
Gökbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118(13):3504-3511.
Commander LA, Seif AE, Insogna IG, Rheingold SR. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol. 2010;150:345-351.
Teachey DT, Devidas M, Wood BL, et al. Children's Oncology Group Trial AALL1231: a Phase III trial testing borezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2022;40(19):2106-2118. doi:10.1200/JCO.21.02678